23 January 2012 – Parsortix update

The group has revealed that its 90% owned portfolio company Parsortix has achieved another major milestone by using its cell separation device to successfully capture circulating tumour cells in cancer patient blood.  Although previously the device had been proven to capture cultured cells added to blood, this is the first time that it has been proved to work with actual patients’blood.  This is further vindication of the technology and, ahead of the company’s interim results, due to be announced on Thursday, we re-iterate our BUY recommendation.